Aldeyra Therapeutics Schedules Webcast and Conference Call to Report First-Quarter 2021 Financial Results and Discuss Recent Business Highlights
Aldeyra Therapeutics (Nasdaq: ALDX) is set to host a conference call on May 6, 2021, at 8:00 a.m. ET to discuss its financial results for Q1 2021, ending March 31, 2021. The live call can be accessed via dial-in numbers for domestic (866-211-4098) and international (647-689-6613) callers. The company focuses on developing innovative therapies for immune-mediated diseases, with lead compounds reproxalap and ADX-629 currently in clinical trials.
- The upcoming conference call will provide insights into Q1 2021 financial results.
- Aldeyra is advancing its clinical pipeline with promising investigational compounds.
- None.
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, May 6, 2021 to report financial results for the quarter ended March 31, 2021 and discuss recent business highlights.
The dial-in numbers are (866) 211-4098 for domestic callers and (647) 689-6613 for international callers. The Conference ID number is 6779202. A live webcast of the conference call will also be available on the Investors & Media page of the company’s corporate website at https://ir.aldeyra.com.
After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.
About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005131/en/
FAQ
What date is Aldeyra's conference call for Q1 2021 financial results?
How can I access Aldeyra's conference call?
What are the lead compounds being developed by Aldeyra?
